This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer’s disease: a pilot study


Carlsson, Cynthia M., Xu, Guofan, Wen, Zhifei, Barnet, Jodi H., Blazel, Hanna M., Chappell, Richard J., Stein, James H., Asthana, Sanjay, Sager, Mark A., Alsop, David C., Rowley, Howard A., Fain, Sean B., Johnson, Sterling C.


Current Alzheimer Research, Volume: 9, No.: 8, Pages.: 990-997

Year of Publication



Background/aims: Hypercholesterolemia in midlife increases risk for Alzheimer’s disease (AD) and contributes to cerebrovascular dysregulation – an early finding in preclinical AD pathology. Statins improve vascular reactivity, but it is unknown if they increase regional cerebral blood flow (CBF) in individuals at risk for AD.; Methods: In a randomized, controlled, double-blind pilot study, 16 asymptomatic middle-aged adults with parental history of AD were randomized to atorvastatin or placebo daily for 4 months. At baseline and month 4, regional CBF was measured using arterial spin-labeling magnetic resonance imaging and endothelial function was measured using brachial artery ultrasound.; Results: At baseline, participants with low HDL-cholesterol, higher global vascular risk, and greater endothelial dysfunction had reduced regional CBF in areas of the brain related to memory and learning (all p < 0.03). Using voxel-based analysis, 4 months of atorvastatin increased CBF in bilateral hippocampi, fusiform gyrus, putamen and insular cortices compared to placebo.; Conclusion: In this pilot study, atorvastatin increased regional CBF in persons at risk for AD. Further research is warranted to confirm whether statins increase CBF in areas of the brain related to memory and learning and whether such perfusion changes are associated with a delay in the onset of AD.; Clinical Trial Registration: Identifier: NCT00751907.;


adult, aged, alzheimer disease, blood, cerebral, cerebrovascular circulation, doubleblind method, drug effects, female, flow, heptanoic acids, humans, hydroxymethylglutarylcoa reductase inhibitors, hypercholesterolemia, male, middle aged, physiopathology, pilot projects, prevention & control, pyrroles, risk factors, therapeutic use

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Risk Factor Modification

Risk Factor Modifications

At risk population